Jpmorgan Chase & CO Kodiak Sciences Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Kodiak Sciences Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 13,913 shares of KOD stock, worth $54,260. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,913

Previous 12,716 9.41%

Holding current value

$54,260

Previous $66,000 51.52%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$2.29 - $4.48 $2,741 - $5,362	1,197 Added 9.41%	13,913 $32,000
Q1 2024 May 10, 2024	SELL	$3.01 - $7.45 $25,004 - $61,887	-8,307 Reduced 39.51%	12,716 $66,000
Q4 2023 Feb 12, 2024	SELL	$1.4 - $3.24 $4,600 - $10,646	-3,286 Reduced 13.52%	21,023 $63,000
Q3 2023 Nov 14, 2023	SELL	$1.8 - $7.49 $1,510 - $6,284	-839 Reduced 3.34%	24,309 $43,000
Q2 2023 Aug 11, 2023	SELL	$4.3 - $9.48 $2,481 - $5,469	-577 Reduced 2.24%	25,148 $173,000
Q1 2023 May 18, 2023	BUY	$4.81 - $8.88 $122,861 - $226,821	25,543 Added 14034.62%	25,725 $159,000
Q1 2023 May 11, 2023	SELL	$4.81 - $8.88 $542,043 - $1 Million	-112,691 Reduced 99.84%	182 $1,000
Q4 2022 Feb 13, 2023	SELL	$6.52 - $8.05 $362,779 - $447,910	-55,641 Reduced 33.02%	112,873 $808,000
Q3 2022 Nov 14, 2022	SELL	$7.57 - $12.5 $2.39 Million - $3.95 Million	-315,927 Reduced 65.21%	168,514 $1.3 Million
Q2 2022 Aug 11, 2022	BUY	$5.04 - $9.48 $401,763 - $755,698	79,715 Added 19.7%	484,441 $3.7 Million
Q1 2022 May 11, 2022	BUY	$7.09 - $89.45 $2.6 Million - $32.9 Million	367,367 Added 983.34%	404,726 $3.12 Million
Q4 2021 Feb 10, 2022	BUY	$80.85 - $128.49 $175,282 - $278,566	2,168 Added 6.16%	37,359 $3.17 Million
Q3 2021 Nov 12, 2021	BUY	$81.97 - $106.94 $2.88 Million - $3.76 Million	35,191 New	35,191 $3.38 Million

Others Institutions Holding KOD

# of Institutions

103

Shares Held

39.8M

Call Options Held

7.6K

Put Options Held

3.5K

View Full List

About Kodiak Sciences Inc.

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $203M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

More about KOD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Kodiak Sciences Inc. Transaction History